Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 911-920 Newer>

HBS Working Knowledge November 17, 2003 Martha Lagace	The Politics of Innovation Mark B. McClellan, the new commissioner of the Food and Drug Administration, described what the FDA is doing to bridge the gap between the high cost of innovation and patients' demand for lower prices.
HBS Working Knowledge November 17, 2003 Martha Lagace	Curbing the Costs of Disease Runaway healthcare costs are driven by multiple symptoms. A conference panel tells how the industry as a whole can get better treatment.
HBS Working Knowledge November 17, 2003 Martha Lagace	The Business Case for Diabetes Disease Management Diabetes is a tough disease to tackle. A case-study discussion led by Harvard professor Nancy Beaulieu asked why it is so complex for business and society, and what might be done to curb its incidence.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
BusinessWeek November 24, 2003 Roger O. Crockett	Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas.
Bio-IT World November 14, 2003 Elizabeth Gardner	Ultimate Analysis With the necessary tools at hand, the race is on to build -- and market -- the first affordable, portable, fully functional DNA analyzer. Is the world ready?
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
Bio-IT World November 14, 2003 Jeff Augen	Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative.
Bio-IT World November 14, 2003 Amnon Shabo	Integrated EHR: The Final Frontier Harmonizing various standards for electronic health records will have far-reaching effects on bioinformatics.
Bio-IT World November 14, 2003 John Dodge	Pfizer's Man with the R&D Plan As Pfizer senior vice president, science and technology, Peter B. Corr oversees $7.1 billion in annual research and development spending, the biggest private R&D budget in the world. In this interview, Corr talks about IT, clinical trials, and his $7-billion budget.
<Older 911-920 Newer> Return to current articles.